poisar

Stocks · News reference

Creative Medical Technology Says All Patients Enrolled And Treated Across ADAPT Trial Of Olastrocel In Chronic Lower Back Pain, Including FDA-Cleared Opioid Expansion Cohort; Trial Moves To Follow-Up And Phase 3 Planning

BenzingaAug 20, 2026, 1:16 PMBenzinga Newsdesk

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Aug 20, 2026, 1:16 PM
Checked
Aug 20, 2026, 1:16 PM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading